Search

Home > Diabetes Knowledge into Practice Podcast > Considerations for offering SGLT2is | With Dr Kevin Fernando
Podcast: Diabetes Knowledge into Practice Podcast
Episode:

Considerations for offering SGLT2is | With Dr Kevin Fernando
Category: Health
Duration: 00:18:09
Publish Date: 2021-06-21 15:20:55
Description:

Following the last episode focusing on GLP-1 RAs, we are now turning to SLGT2 inhibitors. Which patients would benefit most from an SGLT2 inhibitor, and who should we avoid offering one? To help answer these questions, we’re joined by Dr Kevin Fernando, GP Partner and Scottish Lead for the UK Primary Care Diabetes Society.

For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn.

Funding statement:

This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

Disclosures:

Dr Kevin Fernando declares the following:

Advisory Board Member - Lilly, Napp, Boehringer Ingelheim   

Speaker Honorarium - Lilly, Napp, Boehringer Ingelheim   


References:

- Zinman B et al. N Engl J Med. 2015;373(22):2117-2128 [EMPA-REG OUTCOME].

- Neal B et al. N Engl J Med. 2017;377(7):644-657 [CANVAS].

- Wiviott SD et al. N Engl J Med. 2019;380(4):347-357 [DECLARE-TIMI 58].

- Cannon CP et al. N Engl J Med. 2020 Oct 8;383(15):1425-1435 [VERTIS-CV].

- Perkovic V et al. N Engl J Med. 2019;380(24):2295-2306 [CREDENCE].

- McGuire D et al. JAMA Cardiol. 2021; 6(2): 1–11 [CVOT meta-analysis].

- Heerspink H et al. N Engl J Med. 2020 Oct 8;383(15):1436-1446 [DAPA-CKD].

- Packer M et al. N Engl J Med. 2020 Oct 8;383(15):1413-1424 [EMPEROR-Reduced].


Funding statement:

This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp and Dohme Corp., and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.
Total Play: 0